利西拉来

利西拉来（CAS 320367-13-3）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的记载用途

Lixisenatide is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type II diabetes mellitus. It is also available in combination with [insulin glargine] for the same indication.Lixisenatide is a recombinant DNA produced polypeptide analogue of human glucagon-like peptide-1 (GLP-1) which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other antidiabetic agents. Therapy with lixisenatide has not been associated with serum enzyme elevations or with episodes of clinically apparent liver injury.

同义词与商品名

Lixisenatide; Adlyxin; Lyxumia; ZP10A peptide; 320367-13-3; ZP 10; AVE0010; AQVE-10010; AVE 0010; lixisenatida; lixisenatidum; AVE 010; AVE-010; ZP-10; AVE-0010; Des-38-proline-exendine-4 (Heloderma suspectum)-(1-39)-peptidylpenta-L-lysyl-L-lysinamide

GHS 危害分类

Reported hazard statements	H318 (100%), H361 (100%)

H318 (100%): Causes serious eye damage [Danger Serious eye damage/eye irritation]

H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

公开数据库对它的描述

Lixisenatide · CAS 320367-13-3 · C215H347N61O65S. UNII 74O62BB01U.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。